USD
+$0.00
(+0.00%
)At Close (As of Oct 15, 2025)
$1.94B
Market Cap
-
P/E Ratio
-0.43
EPS
$45.07
52 Week High
$21.97
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $249M |
Total Revenue | $389M |
Cost Of Revenue | $140M |
Costof Goods And Services Sold | $140M |
Operating Income | $39M |
Selling General And Administrative | $191M |
Research And Development | $28M |
Operating Expenses | $210M |
Investment Income Net | - |
Net Interest Income | -$33M |
Interest Income | $1.5M |
Interest Expense | $34M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $24M |
Income Before Tax | -$7.5M |
Income Tax Expense | $5.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$13M |
Comprehensive Income Net Of Tax | - |
Ebit | $27M |
Ebitda | $51M |
Net Income | -$13M |
Field | Value (USD) |
---|---|
Total Assets | $789M |
Total Current Assets | $290M |
Cash And Cash Equivalents At Carrying Value | $53M |
Cash And Short Term Investments | $53M |
Inventory | $80M |
Current Net Receivables | $86M |
Total Non Current Assets | $499M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $156M |
Intangible Assets Excluding Goodwill | $156M |
Goodwill | $241M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $71M |
Other Non Current Assets | - |
Total Liabilities | $513M |
Total Current Liabilities | $67M |
Current Accounts Payable | $18M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $5.3M |
Total Non Current Liabilities | $446M |
Capital Lease Obligations | $48M |
Long Term Debt | $314M |
Current Long Term Debt | $195K |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $362M |
Other Current Liabilities | $41M |
Other Non Current Liabilities | $61M |
Total Shareholder Equity | $276M |
Treasury Stock | - |
Retained Earnings | -$61M |
Common Stock | $434K |
Common Stock Shares Outstanding | $42M |
Field | Value (USD) |
---|---|
Operating Cashflow | $22M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $24M |
Capital Expenditures | $11M |
Change In Receivables | - |
Change In Inventory | -$6.1M |
Profit Loss | - |
Cashflow From Investment | -$28M |
Cashflow From Financing | $2.2M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $0 |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$13M |
Field | Value (USD) |
---|---|
Gross Profit | $249M |
Total Revenue | $389M |
Cost Of Revenue | $140M |
Costof Goods And Services Sold | $140M |
Operating Income | $39M |
Selling General And Administrative | $191M |
Research And Development | $28M |
Operating Expenses | $210M |
Investment Income Net | - |
Net Interest Income | -$33M |
Interest Income | $1.5M |
Interest Expense | $34M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $24M |
Income Before Tax | -$7.5M |
Income Tax Expense | $5.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$13M |
Comprehensive Income Net Of Tax | - |
Ebit | $27M |
Ebitda | $51M |
Net Income | -$13M |
Field | Value |
---|---|
Ex Dividend Date | 2015-12-09 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.03 |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Artivion Inc. is a pioneering leader in the field of implantable human tissues and advanced medical devices, dedicated to enhancing surgical outcomes and improving patient care worldwide. With a strong focus on tissue bioengineering and regenerative medicine, the company is at the forefront of innovation, delivering high-quality solutions that meet the evolving demands of the healthcare sector. Artivion's commitment to continuous improvement and excellence positions it as a key player in the medical technology landscape, effectively addressing the pressing needs for sustainable and effective surgical interventions.